Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Small Cell Lung Carcinoma 19Breast Neoplasms 16Sarcoma 12Lung Neoplasms 9Esophageal Squamous Cell Carcinoma 7Carcinoma, Hepatocellular 7Thyroid Neoplasms 6Stomach Neoplasms 6Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Ovarian Neoplasms 5NSCLC 5Carcinoma 5Triple Negative Breast Neoplasms 4Pheochromocytoma 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Neoplasms 3Glioma 3Cholangiocarcinoma 3Brain Neoplasms 3Biliary Tract Neoplasms 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Platinum-resistant Ovarian Cancer 2

Interventions

Pemetrexed 3pembrolizumab 1lenvatinib 1anlotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-squamous Non-small-cell Lung Cancer × anlotinib × Clear all
NCT04453423 2020-07-01

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
90 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡